0000950170-24-026492.txt : 20240305 0000950170-24-026492.hdr.sgml : 20240305 20240305182828 ACCESSION NUMBER: 0000950170-24-026492 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Khayal Tamer I CENTRAL INDEX KEY: 0001430462 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38891 FILM NUMBER: 24723163 MAIL ADDRESS: STREET 1: TRANSMEDICS INC STREET 2: 200 MINUTEMAN ROAD CITY: ANDOVER STATE: MA ZIP: 01810 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TransMedics Group, Inc. CENTRAL INDEX KEY: 0001756262 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 MINUTEMAN ROAD CITY: ANDOVER STATE: MA ZIP: 01810 BUSINESS PHONE: 9785520900 MAIL ADDRESS: STREET 1: 200 MINUTEMAN ROAD CITY: ANDOVER STATE: MA ZIP: 01810 4 1 ownership.xml 4 X0508 4 2024-03-01 0001756262 TransMedics Group, Inc. TMDX 0001430462 Khayal Tamer I C/O TRANSMEDICS GROUP, INC. 200 MINUTEMAN ROAD ANDOVER MA 01810 false true false false Chief Commercial Officer true Common Stock 2024-03-01 4 M false 10000 13.28 A 36502 D Common Stock 2024-03-01 4 S false 2868 81.49 D 33634 D Common Stock 2024-03-01 4 S false 1842 82.28 D 31792 D Common Stock 2024-03-01 4 S false 3632 83.64 D 28160 D Common Stock 2024-03-01 4 S false 424 84.26 D 27736 D Common Stock 2024-03-01 4 S false 1234 85.18 D 26502 D Common Stock 14776 I By the Khayal Family 2021 Irrevocable Trust Common Stock 11051 I By the Tamer Ibrahim Ahmed Khayal Trust Stock Option (Right to Buy) 13.28 2024-03-01 4 M false 10000 0.00 D 2032-02-22 Common Stock 10000 32000 D The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $81.01 to $81.935, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $82.01 to $82.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $83.00 to $83.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $84.07 to $84.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $85.035 to $85.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. By: /s/ Stephen Gordon, Attorney-in-Fact 2024-03-05